Switzerland lowers prices of 300 drugs

As part of its 2025 annual review, the Swiss Federal Office of Public Health (FOPH) has reduced the prices of almost 300 medicines on the speciality list (ES) by an average of 12%, generating savings of at least CHF65 million as of December 1. +Get the most important news from Switzerland in your inbox The criteria used are effectiveness, appropriateness and cost-effectiveness (EAE), the FOPH indicated in a note today. This is an important contribution to cost containment in the health sector. + The high stakes fight over drug prices The drugs concerned mainly treat cardiovascular, respiratory and infectious diseases. For 50% of the original preparations no reduction was necessary, as they are already cost-effective compared to international comparisons. In contrast, for 70% of generics, co-marketing and biosimilars, cuts were triggered. What is your opinion? Join the debate: The three-year review (2023-2025), which examined the last third of medicinal reimbursement by mandatory ...